Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. ViroGates AS's Total Liabilities for the quarter that ended in Mar. 2026 was €1.34 Mil. ViroGates AS's Total Assets for the quarter that ended in Mar. 2026 was €3.58 Mil.
Therefore, ViroGates AS's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2026 was 0.37.
ViroGates AS (FRA:EP2) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
ViroGates AS Liabilities-to-Assets Related Terms
ViroGates AS Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for ViroGates AS's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:EP2 vs ABT, SYK, MDT: Liabilities-to-Assets Comparison
For the Medical Devices subindustry, ViroGates AS's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS Liabilities-to-Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where ViroGates AS's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
ViroGates AS's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroGates AS (FRA:EP2) has a Liabilities-to-Assets of 0.37 as of Mar. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on ViroGates AS and its competitors.
Is ViroGates AS's Liabilities-to-Assets too high?
ViroGates AS's current Liabilities-to-Assets is 0.37. Overall, ViroGates AS has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Liabilities-to-Assets compare to ABT and SYK?
ViroGates AS's Liabilities-to-Assets of 0.37 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?
A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on ViroGates AS and its competitors. ViroGates AS's current Liabilities-to-Assets is 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (FRA:EP2) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.87, compared to a current price of €1.45 — trading 66.7% above its estimated fair value. The current Liabilities-to-Assets is 0.37. ViroGates AS's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For ViroGates AS (FRA:EP2), the current Liabilities-to-Assets is 0.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (FRA:EP2) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of €1.45 is trading 66.7% above its estimated GF Value™ of €0.87.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for FRA:EP2:
Liabilities-to-Assets: 0.37
GF Value™: €0.87 vs. price of €1.45 (66.7% above fair value)
No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
24GF Score
Get the complete analysis for FRA:EP2
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EP2 has been successfully added to your 
